Latest News
Conference Coverage
For AFib cardioversion in obesity, dual energy might be the answer
In patients with obesity, dual energy cardioversion is more reliable and just as safe as conventional single energy cardioversion as an initial...
Conference Coverage
Blood pressure lowering reduces dementia risk
“This proven, effective intervention should be widely scaled up to reduce the global burden of dementia.”
Conference Coverage
Pregnancy in rheumatic disease quadruples risk of cardiovascular events
Pregnant patients with lupus and concomitant APS had an 18-fold higher risk for a cardiovascular event during and up to 6 weeks postpartum than...
Conference Coverage
Pregnancies with low anti-SSA/Ro autoantibody levels: Forgo fetal heart rhythm monitoring?
The ongoing prospective multicenter trial is the largest of its kind.
From the Journals
Salt intake associated with increased type 2 diabetes risk
“These findings provide support that reduction of adding salt to foods may act as a potential behavioral intervention approach for preventing T2D...
Conference Coverage
Sustained reductions in Lp(a) achieved with novel siRNA drug
“At the highest doses, lepodisiran is not just lowering Lp(a), it appears to be getting rid of it.”
Conference Coverage
Dropping aspirin cuts bleeding in LVAD patients: ARIES-HM3
“We’ve always thought that somehow aspirin prevents stroke and prevents clotting and that it’s anti-inflammatory, and what we found in ARIES was...
From the Journals
Classification identifies four stages of heart attack
“Even inside the hospital, we have heterogeneity in mortality risk. But we are not paying attention to one patient differently than the other,...
Conference Coverage
Potential dapagliflozin benefit post MI is not a ‘mandate’
“From my perspective, DAPA-MI does not suggest a new mandate to expand SGLT2 inhibition to an isolated MI population without other SGLT2 inhibitor...
From the Journals
Long COVID and mental illness: New guidance
“Long COVID is real, and mental health conditions do not cause long COVID.”
Conference Coverage
Semaglutide ‘a new pathway’ to CVD risk reduction: SELECT
The SELECT trial was “a turning point in the treatment of obesity and a call to action.”